Skip to main content
editor@jprims.in
9343055451
e-ISSN: 3049-1681
Journal of Pharmaceutical Research and Integrated Medical Sciences

Journal of Pharmaceutical Research and Integrated Medical Sciences

📢 Latest Update: New special issue call for papers on "Pharmaceutical Research and Integrated Medical Sciences" - Submit by September 30, 2026

📢 Latest Update: New special issue call for papers on "Pharmaceutical Research and Integrated Medical Sciences" - Submit by September 30, 2026

Volume 3, Issue 9 - 2026 (JPRIMS, Vol-3, Issue-09, September-2026)

Volume 3 Issue 9 Cover

Issue Details:

Volume 3 Issue 9
Published:Sep 3, 2026

Editorial: JPRIMS, Vol-3, Issue-09, September-2026

Welcome to the 2026 issue of Journal of Pharmaceutical Research and Integrated Medical Sciences. This issue showcases the remarkable breadth and depth of contemporary research across multiple disciplines. From cutting-edge applications of machine learning in climate science to the revolutionary potential of quantum computing in drug discovery, our featured articles demonstrate the power of interdisciplinary collaboration in addressing global challenges.

We are particularly excited to present research that bridges traditional academic boundaries, reflecting our journal's commitment to fostering innovation through cross-disciplinary dialogue. The integration of artificial intelligence with environmental science, the application of blockchain technology to supply chain management, and the convergence of urban planning with smart city technologies exemplify the transformative potential of collaborative research.

As we continue to navigate an era of rapid technological advancement and global challenges, the research presented in this issue offers both insights and solutions that will shape our future. We thank our authors, reviewers, and editorial board members for their continued dedication to advancing knowledge and promoting scientific excellence.

Dr. Arpan Kumar Tripathi
Editor in Chief
Journal of Pharmaceutical Research and Integrated Medical Sciences

Articles in This Issue

Showing 5 of 5 articles
International Peer ReviewedID: JPRIMS930001Pages 1-19Open AccessOpen Access

Multimodal AI and Machine Learning for Predictive Risk Stratification, Early Detection, And Clinical Management of Pica: Integrating Etiological and Pathophysiological Biomarkers

Yash Srivastav, Stuti Verma, Kamini Prajapati, Sandeep Prakash, Rajeev Kumar, Anubha Dhuriya, Anup Kumar Sirbaiya, Shivani Singh

Pica is a clinically significant and often overlooked feeding and eating disorder in which individuals have a persistent urge to eat or chew non-nutritious or non-food items and is linked to nutritional, hematological, behavioral, and environmental issues. Human studies have regularly found links between pica and iron deficiency and anemia, as well as between changes in hematological parameters, decreased ferritin, and decreased zinc concentrations; toxic-element exposure may also be a part of certain behaviors (like geophagia). The review critically summarises the potential use of multimodal artificial intelligence (AI) and machine learning (ML) to support predictive risk stratification, early detection, and clinical management of pica, highlighting the importance of combining etiological and pathophysiological biomarkers, clinical, behavioural, toxicological and electronic health-record data. Biomarker evidence also indicates human exposure to multiple biomarkers together may be a more complete risk profile than single biomarkers, since there are human data from which to draw conclusions. AI and natural language processing could be used to identify undetected pica-related behaviors and track changes over time to clinical and laboratory data. However, there are still limitations in the development and validation of pica-specific AI models, and existing evidence from related conditions mainly methodologically supports the use of AI. Further studies are needed on large, prospective, diverse human cohorts, standardized pica phenotyping, longitudinal assessment of biomarkers, explainable AI, external validation, and prospective clinical assessment. Finally, multimodal AI should be used as a clinically interpretable decision support system, not as an independent diagnostic system.

PicaMultimodal Artificial IntelligenceMachine LearningBiomarkersRisk StratificationEarly Detection.
20,217 views
5,969 downloads

Contributors:

 Yash Srivastav
,
 Stuti Verma
,
 Kamini Prajapati
,
 Sandeep Prakash
,
 Rajeev Kumar
,
 Anubha Dhuriya
,
 Anup Kumar Sirbaiya
,
 Shivani Singh
International Peer ReviewedID: JPRIMS930002Pages 20-57Open AccessOpen Access

Nanotechnology-Augmented Herbal Remedies and Synthetic Substances for Leishmaniasis: An In-Depth Review of Promising Solutions

Deleshwar Kumar, Dr Saurabh Shrivastava

Background: Visceral leishmaniasis (VL), the deadliest form of leishmaniasis, remains endemic in tropical/subtropical regions. Conventional treatments are limited by toxicity, high cost, and emerging drug resistance. Methods: Studies published between 2000–2024 on antileishmanial efficacy of herbal extracts, synthetic drugs, and nanoformulations (liposomes, polymeric nanoparticles, metallic nanocarriers) were analyzed via databases including PubMed, Scopus, and Web of Science following PRISMA guidelines. Results: Gold-standard therapies like liposomal amphotericin‑B (AmBisome®) remain vital but require improved targeting and reduced toxicity. Phytocompounds from Azadirachta indica, Curcuma longa, and Withania somnifera exhibit significant in vitro/in vivo antileishmanial activity. Nanocarriers—liposomes, solid-lipid NPs, polymeric dendrimers, metallic nanoparticles—enhance bioavailability, reduce off‑target effects, and support targeted macrophage uptake. Patents focus on curcumin‑PLGA systems, dendrimer‑mediated combination therapies, and ligand-targeted delivery. Conclusion: Integrating low‑toxicity phytochemicals with nanotechnology platforms offers a promising, next-generation approach to treat VL. Future preclinical standardization and clinical trials are urgently needed. Graphical Abstract

NanotechnologyLeishmaniasisPhytochemicalsSynthetic DrugsHerbal drugsNano-composition.
20,382 views
6,153 downloads

Contributors:

 Deleshwar Kumar
,
 Dr Saurabh Shrivastava
International Peer ReviewedID: JPRIMS930003Pages 58-75Open AccessOpen Access

Microbial Bioremediation for Environmental Sustainability: Recent Developments

Sumangala N

Microbial bioremediation has become an interesting and sustainable technique for dealing with pollution of the environment through microbial degradation, transformation, immobilization, and recovery of contaminants. This review looks into recent developments of microbial bioremediation with focus on pollutants such as wastewater, pharmaceuticals and antibiotics, heavy metals, petroleum hydrocarbons, plastics, microplastics and other emerging pollutants. Mechanisms employed by microbes include biodegradation, biosorption, bioaccumulation and biotransformation together with advancements in the use of bioaugmentation, microbial consortia, microbial electrochemical systems, omics technology, and genetically modified microbes. The reviewed research shows that microbial technologies have the potential of providing efficient pollutant management as well as resource recovery in the form of biogas, microbial biomass, biopolymers, nutrients and metals, thus making circular economy possible. However, some limitations like slow degradation rate, incomplete mineralization, formation of toxic metabolites, instability of the microbes, antibiotic resistance, lack of field studies, scalability issues and biosafety concerns are evident. Future studies should focus on long-term field investigations, realistic environmental matrix, understanding of microbial community dynamics, transformation product identification and use of advanced biotechnology, life cycle assessment and process engineering. In general, microbial bioremediation holds great promise towards sustainable future but development of efficient, safe, scalable, resource recovery and human relevant technologies is crucial.

Microbial BioremediationEnvironmental SustainabilityWastewater TreatmentEmerging ContaminantsMicrobial ConsortiaCircular Economy.
20,141 views
6,043 downloads

Contributors:

 Sumangala N
International Peer ReviewedID: JPRIMS930004Pages 76-87Open AccessOpen Access

Combined Antidepressant Potential of Trigonella Foenum- Graecum and Asparagus Racemosus: A Comprehensive Review

Yukta Verma, Arpan Kumar Tripathi

Methanolic extract of Trigonella foenum- graecum (seed) and Asparagus racemosus(root) were studied in the mice and rat both. The study applied the Force Swim Test (FST) and Tail Suspension Test (TST). Poor mood, low energy, oxidative stress, diminished motivation, and compromised emotional functioning are the main symptoms of depression. Depression is the common neuropsychiatric illness. Medicinal plants like T. foenum- graecum and A. racemosus have possible neuroprotective and mood- modulating qualities which has been prompted by the drawbacks of traditional antidepressant medication. Both T.foenum- graecum and A.racemosus have no of physiologically active components and have been shown to have neuropharmacological and adaptogenic effects. The goal of the current investigation was to assess the antidepressant activity of T. foenum- graecum(seed) and A. racemosus (root) using the FST and TST. The purpose of the study was to evaluate the combination formulation behavioral reaction to that of the control and conventional treatment groups. A. racemosus has shown antidepressant like action which is linked to noradrenergic and serotonergic systems, previous experimental research suggest that flavonoids produced from fenugreek can Affect monoaminergic pathways. Therefore, by modifying neurotransmitter function and associated stress- response pathways, the combination formulations may offer a supplementary pharmaceutical strategy. The outcome of this study may offer initial scientific proof in favor of this herbal combination’s further investigation and mechanistic assessment as a viable antidepressant formulation.

Asparagus racemosusAntidepressant actionTrigonella foenum- graecumTail Suspension TestHerbal formulationOxidative stress+3 more
20,445 views
6,160 downloads

Contributors:

 Yukta Verma
,
 Arpan Kumar Tripathi
Research PaperID: JPRIMS930005Pages 88-95Open AccessOpen Access

Phytochemical Screening and Anthelmintic activity of Ficus religiosa Linn.

Pratibha Jaal, Revendra Parganiha

The present study was designed to evaluate the anthelmintic potential of bark extract of Ficus religiosa Linn. The methanolic extract of Ficus religiosa & its aqueous extract at different concentrations (25, 50,100 mg /ml) were tested on Indian adult earthworm (Pheretimaposthuma) by in vitro standard procedure. Time of paralysis and time of death of the worms were considered as the parameters to assess the anthelmintic action. Albendazole and 2% gum acacia in distilled water were used as standard and control respectively. The methanolic fraction of extract exhibited potent anthelmintic activity compared to aqueous extracts evidenced by significant decrease in time of paralysis & death. Evaluation of anthelmintic activity by aqueous extract at 100mg/ml concentration showed time of paralysis & time of death as 7.01 & 13.20 min. Whereas for methanolic extract fraction, it was 5.4& 8.16 min.The reference standard Albendazole showed the time of paralysis & time of death as 1.22 & 2.30 min. respectivelyThe observed activity could be due to the presence to phenolic compounds, particularly tannins in the test extract. These in-vitro studies indicated that the Ficus religiosa Linn is a significant source of natural anthelmintic, which might be helpful in preventing the progress of various parasitic disorders. Intestinal parasitic infections are one of the main health problems, especially in developing countries, and particularly in children. Inadequate sanitation and poor hygiene may be the reason behind it [1]. Anthelmintic are drugs that either kill or expel infesting helminthes and the gastrointestinal tract is the abode of many helminths, although some also live in tissues, or their larvae migrate into tissues. They harm the host depriving him of food, causing blood loss, injury to organs, intestinal or lymphatic obstruction and by secreting toxins. Helminthiasis is rarely fatal, but is a major cause of morbidity [2]. The world health organization (WHO) has estimated that approximately 80% of the world’s population depends on traditional medicines for meeting their primary health careneeds [3]. Numbers of synthetic drugs like mebendazole, albendazole, piperazine, pyrantel, are used to control and prevent from the infection, used as broad spectrum anthelmintic drug. Long term use of this synthetic medicine associated with various adverse effects like tolerance, resistance, nausea, vomiting, drowsiness, dizziness, and abdominal pain. Therefore, search for new drugs is essential from natural source [4]. Today, gastrointestinal anthelmintic. However, wide-spread increase in anthelmintic resistance, scarcity and high costs, particularly for low-income farmers in developing among other alternative methods [5]. The aim of the study is to evaluate anthelmintic potential of bark extracts of Ficus religiosa.

Methanolic extractAlbendazoleReligiosa Linn
20,431 views
6,286 downloads

Contributors:

 Pratibha Jaal
,
 Revendra Parganiha